Skip to main content
Erschienen in: Clinical and Translational Oncology 3/2014

01.03.2014 | Research Article

Microvesicle microRNA profiles and functional roles between chronic hepatitis B and hepatocellular carcinoma

verfasst von: H. Li, L. Sun, X. Chen, W. Xiong, D. Hu, S. Jie

Erschienen in: Clinical and Translational Oncology | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Objectives

Hepatocellular carcinoma (HCC) is an inflammation-related malignancy and chronic hepatitis B (CHB) predisposes to HCC. Microvesicles (MVs) transfer various bioactive molecules including microRNA (miRNA) between cells and exert biological functions. The purpose of this study was to detect CHB-MV and HCC-MV miRNAs and analyze the expression profiles and functional roles between CHB and HCC.

Methods

We examined MV miRNA profiles of CHB and HCC using miRNA microarrays. TargetScan, PicTar and miRanda were exerted to predict target genes regulating these differentially expressed miRNAs.

Results

A total of 272 and 242 aberrant fluctuation miRNAs were identified in CHB-MVs and HCC-MVs, respectively. Among them, there were 53 miRNAs co-expressing both in CHB-MVs and HCC-MVs. These miRNAs affected cellular apoptosis, proliferation and molecular signaling pathways. Among them, 25 co-expressed MV miRNAs targeted 21 inflammatory factors and these miRNAs may be a tight linkage between CHB and HCC. Interestingly, there were 14 co-expressed MV miRNAs targeting 17 oncogenes and 7 miRNAs targeting 9 tumor suppressors in the study. In addition, MVs were enriched with maladjusted miRNAs regulating zinc finger proteins and chromosome open reading frame. Those MV miRNAs may play roles in CHB developing to HCC.

Conclusions

We demonstrated that CHB and HCC displayed aberrantly co-expressed MV miRNA profiles for the first time, which may have a link between CHB and HCC. Those MV miRNAs may serve as early biomarkers for HCC and may aid to promote CHB developing to HCC.
Literatur
1.
Zurück zum Zitat Block TM, Mehta AS, Fimmel CJ, Jordan R. Molecular viral oncology of hepatocellular carcinoma. Oncogene. 2003;22:5093–107.PubMedCrossRef Block TM, Mehta AS, Fimmel CJ, Jordan R. Molecular viral oncology of hepatocellular carcinoma. Oncogene. 2003;22:5093–107.PubMedCrossRef
3.
Zurück zum Zitat Poehlmann A, Kuester D, Malfertheiner P, Guenther T, Roessner A. Inflammation and Barrett’s carcinogenesis. Pathol Res Pract. 2012;208:269–80.PubMedCrossRef Poehlmann A, Kuester D, Malfertheiner P, Guenther T, Roessner A. Inflammation and Barrett’s carcinogenesis. Pathol Res Pract. 2012;208:269–80.PubMedCrossRef
4.
Zurück zum Zitat Liao R, Sun TW, Yi Y, Wu H, Li YW, Wang JX, et al. Expression of TREM-1 in hepatic stellate cells and prognostic value in hepatitis B-related hepatocellular carcinoma. Cancer Sci. 2012;103:984–92.PubMedCrossRef Liao R, Sun TW, Yi Y, Wu H, Li YW, Wang JX, et al. Expression of TREM-1 in hepatic stellate cells and prognostic value in hepatitis B-related hepatocellular carcinoma. Cancer Sci. 2012;103:984–92.PubMedCrossRef
5.
Zurück zum Zitat Benameur T, Andriantsitohaina R, Martínez MC. Therapeutic potential of plasma membrane-derived microparticles. Pharmacol Rep. 2009;61:49–57.PubMed Benameur T, Andriantsitohaina R, Martínez MC. Therapeutic potential of plasma membrane-derived microparticles. Pharmacol Rep. 2009;61:49–57.PubMed
6.
Zurück zum Zitat Gyorgy B, Szabo TG, Pasztoi M, Pal Z, Misjak P, Aradi B, et al. Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell Mol Life Sci. 2011;68:2667–88.PubMedCentralPubMedCrossRef Gyorgy B, Szabo TG, Pasztoi M, Pal Z, Misjak P, Aradi B, et al. Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell Mol Life Sci. 2011;68:2667–88.PubMedCentralPubMedCrossRef
7.
Zurück zum Zitat Lee TH, D’Asti E, Magnus N, Al-Nedawi K, Meehan B, Rak J. Microvesicles as mediators of intercellular communication in cancer-the emerging science of cellular ‘debris’. Semin Immunopathol. 2011;33:455–67.PubMedCrossRef Lee TH, D’Asti E, Magnus N, Al-Nedawi K, Meehan B, Rak J. Microvesicles as mediators of intercellular communication in cancer-the emerging science of cellular ‘debris’. Semin Immunopathol. 2011;33:455–67.PubMedCrossRef
8.
Zurück zum Zitat Mathivanan S, Ji H, Simpson RJ. Exosomes: extracellular organelles important in intercellular communication. J Proteomics. 2010;73:1907–20.PubMedCrossRef Mathivanan S, Ji H, Simpson RJ. Exosomes: extracellular organelles important in intercellular communication. J Proteomics. 2010;73:1907–20.PubMedCrossRef
9.
Zurück zum Zitat Simons M, Raposo G. Exosomes-vesicular carriers for intercellular communication. Curr Opin Cell Biol. 2009;21:575–81.PubMedCrossRef Simons M, Raposo G. Exosomes-vesicular carriers for intercellular communication. Curr Opin Cell Biol. 2009;21:575–81.PubMedCrossRef
10.
11.
Zurück zum Zitat Dalli J, Norling LV, Renshaw D, Cooper D, Leung KY, Perretti M, et al. Annexin 1 mediates the rapid anti-inflammatory effects of neutrophil-derived microparticles. Blood. 2008;112:2512–9.PubMedCrossRef Dalli J, Norling LV, Renshaw D, Cooper D, Leung KY, Perretti M, et al. Annexin 1 mediates the rapid anti-inflammatory effects of neutrophil-derived microparticles. Blood. 2008;112:2512–9.PubMedCrossRef
12.
Zurück zum Zitat Schetter AJ, Heegaard NH, Harris CC. Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis. 2010;31:37–49.PubMedCrossRef Schetter AJ, Heegaard NH, Harris CC. Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis. 2010;31:37–49.PubMedCrossRef
13.
Zurück zum Zitat Gui J, Tian Y, Wen X, Zhang W, Zhang P, Gao J, et al. Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies. Clin Sci (Lond). 2011;120:183–93.CrossRef Gui J, Tian Y, Wen X, Zhang W, Zhang P, Gao J, et al. Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies. Clin Sci (Lond). 2011;120:183–93.CrossRef
14.
Zurück zum Zitat Hunter MP, Ismail N, Zhang X, Aguda BD, Lee EJ, Yu L, et al. Detection of microRNA expression in human peripheral blood microvesicles. PLoS ONE. 2008;3:e3694.PubMedCentralPubMedCrossRef Hunter MP, Ismail N, Zhang X, Aguda BD, Lee EJ, Yu L, et al. Detection of microRNA expression in human peripheral blood microvesicles. PLoS ONE. 2008;3:e3694.PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005;433:769–73.PubMedCrossRef Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005;433:769–73.PubMedCrossRef
16.
Zurück zum Zitat Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N, et al. Widespread changes in protein synthesis induced by microRNAs. Nature. 2008;455:58–63.PubMedCrossRef Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N, et al. Widespread changes in protein synthesis induced by microRNAs. Nature. 2008;455:58–63.PubMedCrossRef
18.
Zurück zum Zitat Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004;64:3753–6.PubMedCrossRef Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004;64:3753–6.PubMedCrossRef
19.
Zurück zum Zitat Han YF, Zhao J, Ma LY, Yin JH, Chang WJ, Zhang HW, et al. Factors predicting occurrence and prognosis of hepatitis- B-virus-related hepatocellular carcinoma. World J Gastroenterol. 2011;17:4258–70.PubMedCrossRef Han YF, Zhao J, Ma LY, Yin JH, Chang WJ, Zhang HW, et al. Factors predicting occurrence and prognosis of hepatitis- B-virus-related hepatocellular carcinoma. World J Gastroenterol. 2011;17:4258–70.PubMedCrossRef
20.
Zurück zum Zitat Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y. Cytokines in cancer immunity and immunotherapy. Immunol Rev. 2004;202:275–93.PubMedCrossRef Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y. Cytokines in cancer immunity and immunotherapy. Immunol Rev. 2004;202:275–93.PubMedCrossRef
21.
Zurück zum Zitat Li N, Fu H, Tie Y, Hu Z, Kong W, Wu Y, et al. miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett. 2009;275:44–53.PubMedCrossRef Li N, Fu H, Tie Y, Hu Z, Kong W, Wu Y, et al. miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett. 2009;275:44–53.PubMedCrossRef
23.
Zurück zum Zitat Chen L, Zhang Q, Chang W, Du Y, Zhang H, Cao G. Viral and host inflammation-related factorsthat can predict the prognosis of hepatocellular carcinoma. Eur J Cancer. 2012;48:1977–87.PubMedCrossRef Chen L, Zhang Q, Chang W, Du Y, Zhang H, Cao G. Viral and host inflammation-related factorsthat can predict the prognosis of hepatocellular carcinoma. Eur J Cancer. 2012;48:1977–87.PubMedCrossRef
24.
Zurück zum Zitat Fan HB, Guo YB, Wang BJ, Zhu YF, Wu AH, Hou JL, et al. Expression of IFN-alpha/beta receptor in the PBMCs and liver of patients with hepatitis B and its clinical significance. Nan Fang Yi Ke Da Xue Xue Bao. 2008;28:979–81.PubMed Fan HB, Guo YB, Wang BJ, Zhu YF, Wu AH, Hou JL, et al. Expression of IFN-alpha/beta receptor in the PBMCs and liver of patients with hepatitis B and its clinical significance. Nan Fang Yi Ke Da Xue Xue Bao. 2008;28:979–81.PubMed
25.
Zurück zum Zitat Liu AM, Yao TJ, Wang W, Wong KF, Lee NP, Fan ST, et al. Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ Open. 2012;2:e000825.PubMedCentralPubMedCrossRef Liu AM, Yao TJ, Wang W, Wong KF, Lee NP, Fan ST, et al. Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ Open. 2012;2:e000825.PubMedCentralPubMedCrossRef
26.
Zurück zum Zitat Zhao A, Zeng Q, Xie X, Zhou J, Yue W, Li Y, et al. MicroRNA-125b induces cancer cell apoptosis through suppression of Bcl-2 expression. J Genet Genomics. 2012;39:29–35.PubMedCrossRef Zhao A, Zeng Q, Xie X, Zhou J, Yue W, Li Y, et al. MicroRNA-125b induces cancer cell apoptosis through suppression of Bcl-2 expression. J Genet Genomics. 2012;39:29–35.PubMedCrossRef
27.
Zurück zum Zitat Wang WH, Studach LL, Andrisani OM. Proteins ZNF198 and SUZ12 are down-regulated in hepatitis B virus (HBV) X protein-mediated hepatocyte transformation and in HBV replication. Hepatology. 2011;53:1137–47.PubMedCentralPubMedCrossRef Wang WH, Studach LL, Andrisani OM. Proteins ZNF198 and SUZ12 are down-regulated in hepatitis B virus (HBV) X protein-mediated hepatocyte transformation and in HBV replication. Hepatology. 2011;53:1137–47.PubMedCentralPubMedCrossRef
28.
Zurück zum Zitat Hu HM, Chen Y, Liu L, Zhang CG, Wang W, Gong K, et al. C1orf61 acts as a tumor activator in human hepatocellular carcinoma and is associated with tumorigenesis and metastasis. FASEB J. 2013;27:163–73.PubMedCrossRef Hu HM, Chen Y, Liu L, Zhang CG, Wang W, Gong K, et al. C1orf61 acts as a tumor activator in human hepatocellular carcinoma and is associated with tumorigenesis and metastasis. FASEB J. 2013;27:163–73.PubMedCrossRef
29.
Zurück zum Zitat Sakai M, Shimokawa T, Kobayashi T, Matsushima S, Yamada Y, Nakamura Y, et al. Elevated expression of C10orf3 (chromosome 10 open reading frame 3) is involved in the growth of human colon tumor. Oncogene. 2006;25:480–6.PubMed Sakai M, Shimokawa T, Kobayashi T, Matsushima S, Yamada Y, Nakamura Y, et al. Elevated expression of C10orf3 (chromosome 10 open reading frame 3) is involved in the growth of human colon tumor. Oncogene. 2006;25:480–6.PubMed
30.
Zurück zum Zitat Jing Z, Yuan X, Zhang J, Huang X, Zhang Z, Liu J, et al. Chromosome 1 open reading frame 190 promotes activation of NF-κB canonical pathway and resistance of dendritic cells to tumor-associated inhibition in vitro. J Immunol. 2010;185:6719–27.PubMedCrossRef Jing Z, Yuan X, Zhang J, Huang X, Zhang Z, Liu J, et al. Chromosome 1 open reading frame 190 promotes activation of NF-κB canonical pathway and resistance of dendritic cells to tumor-associated inhibition in vitro. J Immunol. 2010;185:6719–27.PubMedCrossRef
Metadaten
Titel
Microvesicle microRNA profiles and functional roles between chronic hepatitis B and hepatocellular carcinoma
verfasst von
H. Li
L. Sun
X. Chen
W. Xiong
D. Hu
S. Jie
Publikationsdatum
01.03.2014
Verlag
Springer Milan
Erschienen in
Clinical and Translational Oncology / Ausgabe 3/2014
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-013-1078-1

Weitere Artikel der Ausgabe 3/2014

Clinical and Translational Oncology 3/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.